BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 32576617)

  • 1. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK.
    O'Connell K; Hamilton-Shield A; Woodhall M; Messina S; Mariano R; Waters P; Ramdas S; Leite MI; Palace J
    J Neurol Neurosurg Psychiatry; 2020 Oct; 91(10):1126-1128. PubMed ID: 32576617
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China.
    Yang CS; Zhang DQ; Wang JH; Jin WN; Li MS; Liu J; Zhang CJ; Li T; Shi FD; Yang L
    CNS Neurosci Ther; 2014 Jan; 20(1):32-9. PubMed ID: 23890015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis Optica Spectrum Disorders.
    Akaishi T; Nakashima I; Sato DK; Takahashi T; Fujihara K
    Neuroimaging Clin N Am; 2017 May; 27(2):251-265. PubMed ID: 28391784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and MRI phenotype of children with MOG antibodies.
    Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
    Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    de Seze J
    Curr Opin Neurol; 2019 Feb; 32(1):111-114. PubMed ID: 30562266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience.
    Martín-Nares E; Hernandez-Molina G; Fragoso-Loyo H
    Lupus; 2019 Oct; 28(11):1302-1311. PubMed ID: 31566079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of myelin oligodendrocyte glycoprotein antibodies for detection of demyelinating optic neuritis].
    Wei SH; Zhao Y
    Zhonghua Yan Ke Za Zhi; 2017 Nov; 53(11):874-877. PubMed ID: 29141393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    Ungureanu A; de Seze J; Ahle G; Sellal F
    Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid eosinophils in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
    Kornbluh AB; Campano VM; Har C; Dwivedi P; Suslovic W; Sepeta L; Kahn I
    Mult Scler Relat Disord; 2024 May; 85():105526. PubMed ID: 38489945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.
    Hofer LS; Ramberger M; Gredler V; Pescoller AS; Rostásy K; Sospedra M; Hegen H; Berger T; Lutterotti A; Reindl M
    Front Immunol; 2020; 11():1188. PubMed ID: 32625206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
    Tajfirouz DA; Bhatti MT; Chen JJ
    Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients.
    Siritho S; Sato DK; Kaneko K; Fujihara K; Prayoonwiwat N
    Mult Scler; 2016 Jun; 22(7):964-8. PubMed ID: 26498263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.